Replies to post #193119 on Biotech Values

[DewDiligence]

MDCO’s (laconic) PR on the Angiomax patent ruling:

http://finance.yahoo.com/news/federal-circuit-rules-against-medicines-163400283.html

I still don’t understand why MDCO is trading higher today.

[DewDiligence]

PJ raises EGRX price target to $94:

$EGRX PIPER raises PT to $94 cc @DewDiligence $mdco pic.twitter.com/OjTmB00l4d

— Isaac M (@ymscapital) July 6, 2015

[DewDiligence]

HSP/(PFE) launches generic Angiomax in US:

http://finance.yahoo.com/news/hospira-announces-u-launch-generic-195900623.html

This launch was a fait accompli following the Appellate Court ruling on the Angiomax patent two weeks ago (#msg-115121863).

p.s. The 7/2/15 ruling initially caused EGRX to sell off, but it has since recovered and set a new all-time high.

[DewDiligence]

MDCO/EGRX/PFE—CAFC agrees to en banc rehearing of Angiomax patent case:

https://twitter.com/danravicher/status/665236027972435968

Please see #msg-115121863 for background.

The en banc rehearing is potentially positive for EGRX because it has a ready-to-use liquid formulation of Angiomax (PDUFA date 3/20/6) that MDCO now has an enhanced motivation to license. (The MDCO patent in question expires in 2029.)